LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.480
-0.040 (-2.63%)
Nov 21, 2024, 4:00 PM EST - Market closed

Company Description

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.

The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.

The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies.

LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207.

LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LAVA Therapeutics N.V.
LAVA Therapeutics logo
Country Netherlands
Founded 2016
IPO Date Mar 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Stephen Hurly

Contact Details

Address:
Yalelaan 62
Utrecht, 3584 CM
Netherlands
Phone 31 85 016 3100
Website lavatherapeutics.com

Stock Details

Ticker Symbol LVTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001840748
CUSIP Number N51517105
ISIN Number NL0015000AG6
SIC Code 2834

Key Executives

Name Position
Stephen Allen Hurly M.B.A., M.Sc. Chief Executive Officer, President and Executive Director
Fred M. Powell CPA Chief Financial Officer
Dr. Hans van der Vliet M.D., Ph.D. Chief Scientific Officer
Amy Garabedian J.D. General Counsel and Corporate Secretary
Wouter van Hunnik Vice President and Head of Human Resources
Dr. Ton Adang Ph.D. Chief Development Officer
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Aug 20, 2024 6-K Report of foreign issuer
Jun 20, 2024 6-K Report of foreign issuer
Jun 6, 2024 6-K Report of foreign issuer
May 21, 2024 6-K Report of foreign issuer
Mar 21, 2024 6-K Report of foreign issuer
Mar 20, 2024 20-F Annual and transition report of foreign private issuers
Mar 7, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 16, 2023 6-K Report of foreign issuer
Nov 9, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership